Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AK119 in healthy subjects
NCT04516564Phase 1Completed
- Sponsor
- Akeso, Inc.
- Start
- Sep 2020
- Primary completion
- May 2021
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing AK119 with Placebo (2 arms). Primary endpoint: Incidence of treatment-emergent adverse events at 64 days. Started Sep 2020; status: completed.
02
Drugs
drebuxelimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04516564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04516564.